Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Titan down on schizophrenia data

TTP was down $2.26 (58%) to $1.63 on 3.9 million shares on Monday after 150-patient cardiac safety study by partner

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE